Key facts
- IMBiologics (KRX: 493280)’s last known valuation is $261.7M (Mar 2026).
- It has raised $99.1M; the latest was IPO ($35.4M) in Mar 2026.
- Notable investors include KB Investment, Korea Development Bank, IMM Investment, Shinhan Venture Investment, Partners Investment — 22 tracked in total.
- Status: Publicly Held.
- ·The complete investor list — 22 names
- ·Watchlist + deal alerts for IMBiologics (KRX: 493280)
- ·The full record, as it builds
Funding rounds
No funding rounds for IMBiologics (KRX: 493280) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About IMBiologics (KRX: 493280)
IMBiologics Corp is a next-generation biopharmaceutical company developing antibody therapeutics. Its proprietary IM-OpDECon platform enables the design of differentiated biologics targeting autoimmune diseases and immuno-oncology. The group leverages diverse antibody modalities to tackle critical unmet medical needs beyond the reach of current therapies. Its business areas are Antibody Research & Development and Autoimmune Diseases Immuno-Oncology. The group's pipeline products are IMB-101/102, IMB-201, and IMB-402.
- Sector
- Healthcare
- HQ
- Suwon-si, South Korea
- Founded
- 2020
- Employees
- 25
- Website
- imbiologics.com/
- Ownership
- Publicly Held
IMBiologics (KRX: 493280) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in IMBiologics (KRX: 493280) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on IMBiologics (KRX: 493280) in its N-PORT filings yet. We sweep new filings monthly.